OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	99
Monoclonal Gammopathy-Associated Neuropathy	28
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	27
Management of Chronic Myeloid Leukemia in Children and Young Adults	24
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	19
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	17
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	17
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	16
Treatment-Free Remission: the New Goal in CML Therapy	16
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	14
Value in Myeloma Care: Myth or Reality	14
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	13
Targeting Apoptosis in ALL	13
Challenges in Chronic Myeloid Leukemia Management in South America	13
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses	12
Prognostic and Predictive Models in Myelofibrosis	12
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic	12
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	12
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	11
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	11
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	10
How Do We Manage Chronic Lymphocytic Leukemia in India	10
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	10
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies	10
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	9

Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	9
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	9
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	8
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	8
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	8
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia	7
Avapritinib in the Treatment of Systemic Mastocytosis: an Update	7
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	7
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	7
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	7
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	7
Pediatric Germline Predisposition to Myeloid Neoplasms	6
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	6
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	6
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	6
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	6
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	6
Myeloproliferative Neoplasms with Monocytosis	6
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	6
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	5
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	5
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	5
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	5
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	5
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	5
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	5
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	4
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	4
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	4
Real-world Management of CML: Outcomes and Treatment Patterns	4
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera	4
Measurable Residual Disease Monitoring in Lymphoma	4
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	3
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	3
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	3
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	3
Managing Survivorship after Hematopoietic Cell Transplantation	3
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	3
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	3
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	3
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	3